Ity. three. Benefits Characteristics with the chosen studies: We identified 5792 citations, of
Ity. three. Results Characteristics of the selected research: We identified 5792 citations, of which 113 have been retained for full-text evaluation. Twelve articles [12,177], reporting Benidipine Purity & Documentation information on 7011 COVID-19 Diversity Library Physicochemical Properties individuals and 1,006,484 non-COVID-19 sufferers, have been finally included (Figure 1).Figure 1. PRISMA flow chart of included studies.The traits with the research are reported in (Table 1).J. Clin. Med. 2021, 10,four ofTable 1. Characteristics of studies evaluating VTE in COVID-19 versus non-COVID-19 cohorts.Study DalagerPedersen et al. 2021 [17] Freund et al. 2020 [18] Helms et al. 2020 [19] Mei et al. 2020 [20] Pellegrini et al. 2021 [21] Poissy et al. 2020 [22] Reider et al. 2020 [23] Boyd et al. 2021 [25] Smilowitz et al. 2021 [26] BurkhardKoren et al. 2021 [27] Stals et al. 2021 [12] Doyle et al. 2021 [24] Nation Design Retrospective cohort study (Registry study) Retrospective cohort study Prospective with historical manage group Retrospective cohort study Potential cohort study Retrospective cohort study Prospective cohort study Retrospective cohort study Retrospective cohort study (registry study) Autoptic study Retrospective cohort study (Registry study) Retrospective cohort study Diagnosis COVID-19 vs. Non-COVID-19 vs. Influenza COVID-19 vs. non-COVID-19 COVID-19 vs. Non-COVID-19 ARDS COVID-19 vs. communityacquired pneumonia COVID-19 vs. non-COVID-19 COVID-19 vs. Influenza COVID-19 vs. non-COVID-19 COVID-19 vs. Influenza COVID-19 vs. viral pneumonia COVID-19 vs. Influenza COVID-19 vs. Influenza COVID-19 vs. Influenza n 1540 vs. 26,131 vs. 9599 Male Sex Age (Years) 72.0 (58.0; 81.0) vs. 68.0 (48.0; 78.0) vs. 70.0 (59.0; 80.0) 61.0 19.0 61.0 19.0 68.0 (61.0; 75.0) vs. 72.0 (61.0; 80.0) 55.five (CI 0.57.0) vs. 61.0 (CI 15.05.0) 56.0 13.0 vs. 57.0 20.0 NA 60.0 (48.five; 71.5) vs. 60.0 (43.five; 76.five) 57.9 14.8 vs. 61.0 17.four 68.5 vs. 62.eight 70 (CI 346) vs. 46 (CI 14) 69.0 19.0 vs. 67.0 13.0 48.three (38.7; 57.3) vs. 46.1 (35.six; 53.2) Main WardDenmark France, Spain, Belgium, Italy, Chile, Canada France56.6 vs. 50.NA974 vs.48.0 vs. 48.EW77 vs.81.8 vs. 77.ICUChina256 vs.51.two vs. 58.NABrazil France Germany Ireland United states of America Switzerland57 vs. 13 107 vs. 40 49 vs. 141 38 vs. 38 3334 vs. 954 521 75 vs. 12 579 vs. 13,217 (GW) 138 vs. 805 (ICU) 51 vs.52.six vs. 53.eight NA 61.2 vs. 50.four 73.7 vs. 52.6 50.9 vs. 42.ICU ICU EW ICU NA72 vs.NAThe Netherlands United Kingdom48.0 vs. 66.0 (GW and ICU) 59.0 vs. 74.GW ICU ICUCountry: country in which the study has been carried out. n: quantity of individuals evaluated in the single study. Age: age is expressed as mean Normal deviation, or as imply (95 Confidence interval), or as imply (25th percentile; 75th percentile) according to the information readily available in every study. EW: emergency ward. GW: common ward. ICU: intensive care unit. NA: data not obtainable.Eight research have been retrospective [12,17,18,20,22,246], three were potential [19,21,23], and one was an autoptic evaluation [27]. Six studies integrated individuals admitted in to the ICU [12,19,21,22,24,25], although two research were performed in emergency departments [18,23]. Six research compared COVID19 individuals with influenza patients [12,17,22,24,25,27], and two studies incorporated community and viral pneumonia [20,26]. Main outcome: The RD for VTE amongst COVID-19 individuals in comparison to nonCOVID-19 individuals was 0.06 (95 CI 0.01.11, p = 0.011, I2 = 97 ), and 0.16 in ICU (95 CI 0.045.27, p = 0.006, I2 = 80 ). (Figure 2). The RD for VTE among COVID-19 individuals in comparison with non-COV.